nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Alkylating Activity—Mitomycin—urinary bladder cancer	0.502	0.569	CiPCiCtD
Temozolomide—Alkylating Activity—Thiotepa—urinary bladder cancer	0.38	0.431	CiPCiCtD
Temozolomide—CYP3A4—Thiotepa—urinary bladder cancer	0.0172	0.687	CbGbCtD
Temozolomide—CYP3A4—Etoposide—urinary bladder cancer	0.00466	0.186	CbGbCtD
Temozolomide—CYP3A4—Doxorubicin—urinary bladder cancer	0.00318	0.127	CbGbCtD
Temozolomide—Diarrhoea—Gemcitabine—urinary bladder cancer	4.12e-05	0.000445	CcSEcCtD
Temozolomide—Erythema multiforme—Methotrexate—urinary bladder cancer	4.1e-05	0.000442	CcSEcCtD
Temozolomide—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	4.1e-05	0.000442	CcSEcCtD
Temozolomide—Urticaria—Etoposide—urinary bladder cancer	4.09e-05	0.000441	CcSEcCtD
Temozolomide—Haemoglobin—Epirubicin—urinary bladder cancer	4.08e-05	0.00044	CcSEcCtD
Temozolomide—Stomatitis—Doxorubicin—urinary bladder cancer	4.08e-05	0.00044	CcSEcCtD
Temozolomide—Abdominal pain—Etoposide—urinary bladder cancer	4.07e-05	0.000439	CcSEcCtD
Temozolomide—Body temperature increased—Etoposide—urinary bladder cancer	4.07e-05	0.000439	CcSEcCtD
Temozolomide—Urinary tract infection—Doxorubicin—urinary bladder cancer	4.07e-05	0.000439	CcSEcCtD
Temozolomide—Hepatitis—Epirubicin—urinary bladder cancer	4.06e-05	0.000438	CcSEcCtD
Temozolomide—Haemorrhage—Epirubicin—urinary bladder cancer	4.06e-05	0.000438	CcSEcCtD
Temozolomide—Eye disorder—Methotrexate—urinary bladder cancer	4.05e-05	0.000437	CcSEcCtD
Temozolomide—Diarrhoea—Fluorouracil—urinary bladder cancer	4.05e-05	0.000437	CcSEcCtD
Temozolomide—Tinnitus—Methotrexate—urinary bladder cancer	4.05e-05	0.000436	CcSEcCtD
Temozolomide—Hypoaesthesia—Epirubicin—urinary bladder cancer	4.04e-05	0.000436	CcSEcCtD
Temozolomide—Asthenia—Cisplatin—urinary bladder cancer	4.03e-05	0.000435	CcSEcCtD
Temozolomide—Pharyngitis—Epirubicin—urinary bladder cancer	4.03e-05	0.000435	CcSEcCtD
Temozolomide—Cardiac disorder—Methotrexate—urinary bladder cancer	4.03e-05	0.000434	CcSEcCtD
Temozolomide—Urinary tract disorder—Epirubicin—urinary bladder cancer	4.01e-05	0.000433	CcSEcCtD
Temozolomide—Oedema peripheral—Epirubicin—urinary bladder cancer	4e-05	0.000431	CcSEcCtD
Temozolomide—Connective tissue disorder—Epirubicin—urinary bladder cancer	3.99e-05	0.00043	CcSEcCtD
Temozolomide—Urethral disorder—Epirubicin—urinary bladder cancer	3.98e-05	0.000429	CcSEcCtD
Temozolomide—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	3.96e-05	0.000427	CcSEcCtD
Temozolomide—Angiopathy—Methotrexate—urinary bladder cancer	3.94e-05	0.000425	CcSEcCtD
Temozolomide—Sinusitis—Doxorubicin—urinary bladder cancer	3.93e-05	0.000424	CcSEcCtD
Temozolomide—Immune system disorder—Methotrexate—urinary bladder cancer	3.92e-05	0.000423	CcSEcCtD
Temozolomide—Dizziness—Fluorouracil—urinary bladder cancer	3.92e-05	0.000423	CcSEcCtD
Temozolomide—Visual impairment—Epirubicin—urinary bladder cancer	3.91e-05	0.000422	CcSEcCtD
Temozolomide—Mediastinal disorder—Methotrexate—urinary bladder cancer	3.91e-05	0.000422	CcSEcCtD
Temozolomide—Chills—Methotrexate—urinary bladder cancer	3.89e-05	0.00042	CcSEcCtD
Temozolomide—Diarrhoea—Cisplatin—urinary bladder cancer	3.84e-05	0.000415	CcSEcCtD
Temozolomide—Erythema multiforme—Epirubicin—urinary bladder cancer	3.84e-05	0.000414	CcSEcCtD
Temozolomide—Alopecia—Methotrexate—urinary bladder cancer	3.83e-05	0.000414	CcSEcCtD
Temozolomide—Vomiting—Gemcitabine—urinary bladder cancer	3.83e-05	0.000413	CcSEcCtD
Temozolomide—Mental disorder—Methotrexate—urinary bladder cancer	3.8e-05	0.00041	CcSEcCtD
Temozolomide—Rash—Gemcitabine—urinary bladder cancer	3.8e-05	0.00041	CcSEcCtD
Temozolomide—Dermatitis—Gemcitabine—urinary bladder cancer	3.8e-05	0.000409	CcSEcCtD
Temozolomide—Eye disorder—Epirubicin—urinary bladder cancer	3.79e-05	0.000409	CcSEcCtD
Temozolomide—Hypersensitivity—Etoposide—urinary bladder cancer	3.79e-05	0.000409	CcSEcCtD
Temozolomide—Tinnitus—Epirubicin—urinary bladder cancer	3.79e-05	0.000408	CcSEcCtD
Temozolomide—Malnutrition—Methotrexate—urinary bladder cancer	3.78e-05	0.000407	CcSEcCtD
Temozolomide—Erythema—Methotrexate—urinary bladder cancer	3.78e-05	0.000407	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—urinary bladder cancer	3.78e-05	0.000407	CcSEcCtD
Temozolomide—Headache—Gemcitabine—urinary bladder cancer	3.78e-05	0.000407	CcSEcCtD
Temozolomide—Flushing—Epirubicin—urinary bladder cancer	3.77e-05	0.000406	CcSEcCtD
Temozolomide—Cardiac disorder—Epirubicin—urinary bladder cancer	3.77e-05	0.000406	CcSEcCtD
Temozolomide—Vomiting—Fluorouracil—urinary bladder cancer	3.77e-05	0.000406	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—urinary bladder cancer	3.76e-05	0.000405	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—urinary bladder cancer	3.76e-05	0.000405	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—urinary bladder cancer	3.74e-05	0.000403	CcSEcCtD
Temozolomide—Rash—Fluorouracil—urinary bladder cancer	3.74e-05	0.000403	CcSEcCtD
Temozolomide—Dermatitis—Fluorouracil—urinary bladder cancer	3.73e-05	0.000403	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—urinary bladder cancer	3.73e-05	0.000402	CcSEcCtD
Temozolomide—Headache—Fluorouracil—urinary bladder cancer	3.71e-05	0.0004	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—urinary bladder cancer	3.71e-05	0.0004	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—urinary bladder cancer	3.7e-05	0.000399	CcSEcCtD
Temozolomide—Dysgeusia—Methotrexate—urinary bladder cancer	3.7e-05	0.000399	CcSEcCtD
Temozolomide—Asthenia—Etoposide—urinary bladder cancer	3.69e-05	0.000398	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—urinary bladder cancer	3.69e-05	0.000398	CcSEcCtD
Temozolomide—Angiopathy—Epirubicin—urinary bladder cancer	3.68e-05	0.000397	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—urinary bladder cancer	3.68e-05	0.000397	CcSEcCtD
Temozolomide—Immune system disorder—Epirubicin—urinary bladder cancer	3.67e-05	0.000396	CcSEcCtD
Temozolomide—Mediastinal disorder—Epirubicin—urinary bladder cancer	3.66e-05	0.000395	CcSEcCtD
Temozolomide—Back pain—Methotrexate—urinary bladder cancer	3.65e-05	0.000394	CcSEcCtD
Temozolomide—Chills—Epirubicin—urinary bladder cancer	3.64e-05	0.000393	CcSEcCtD
Temozolomide—Pruritus—Etoposide—urinary bladder cancer	3.64e-05	0.000393	CcSEcCtD
Temozolomide—Visual impairment—Doxorubicin—urinary bladder cancer	3.62e-05	0.000391	CcSEcCtD
Temozolomide—Alopecia—Epirubicin—urinary bladder cancer	3.59e-05	0.000387	CcSEcCtD
Temozolomide—Nausea—Gemcitabine—urinary bladder cancer	3.58e-05	0.000386	CcSEcCtD
Temozolomide—Vomiting—Cisplatin—urinary bladder cancer	3.57e-05	0.000385	CcSEcCtD
Temozolomide—Vision blurred—Methotrexate—urinary bladder cancer	3.56e-05	0.000384	CcSEcCtD
Temozolomide—Mental disorder—Epirubicin—urinary bladder cancer	3.56e-05	0.000384	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—urinary bladder cancer	3.55e-05	0.000383	CcSEcCtD
Temozolomide—Rash—Cisplatin—urinary bladder cancer	3.54e-05	0.000382	CcSEcCtD
Temozolomide—Dermatitis—Cisplatin—urinary bladder cancer	3.54e-05	0.000382	CcSEcCtD
Temozolomide—Malnutrition—Epirubicin—urinary bladder cancer	3.53e-05	0.000381	CcSEcCtD
Temozolomide—Erythema—Epirubicin—urinary bladder cancer	3.53e-05	0.000381	CcSEcCtD
Temozolomide—Diarrhoea—Etoposide—urinary bladder cancer	3.52e-05	0.00038	CcSEcCtD
Temozolomide—Nausea—Fluorouracil—urinary bladder cancer	3.52e-05	0.00038	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—urinary bladder cancer	3.51e-05	0.000379	CcSEcCtD
Temozolomide—Ill-defined disorder—Methotrexate—urinary bladder cancer	3.5e-05	0.000378	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—urinary bladder cancer	3.5e-05	0.000378	CcSEcCtD
Temozolomide—Anaemia—Methotrexate—urinary bladder cancer	3.49e-05	0.000377	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—urinary bladder cancer	3.49e-05	0.000376	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—urinary bladder cancer	3.49e-05	0.000376	CcSEcCtD
Temozolomide—Dysgeusia—Epirubicin—urinary bladder cancer	3.46e-05	0.000373	CcSEcCtD
Temozolomide—Back pain—Epirubicin—urinary bladder cancer	3.42e-05	0.000369	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—urinary bladder cancer	3.41e-05	0.000368	CcSEcCtD
Temozolomide—Malaise—Methotrexate—urinary bladder cancer	3.41e-05	0.000367	CcSEcCtD
Temozolomide—Dizziness—Etoposide—urinary bladder cancer	3.4e-05	0.000367	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—urinary bladder cancer	3.39e-05	0.000366	CcSEcCtD
Temozolomide—Vertigo—Methotrexate—urinary bladder cancer	3.39e-05	0.000366	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—urinary bladder cancer	3.39e-05	0.000365	CcSEcCtD
Temozolomide—Leukopenia—Methotrexate—urinary bladder cancer	3.38e-05	0.000365	CcSEcCtD
Temozolomide—Chills—Doxorubicin—urinary bladder cancer	3.37e-05	0.000364	CcSEcCtD
Temozolomide—Nausea—Cisplatin—urinary bladder cancer	3.34e-05	0.00036	CcSEcCtD
Temozolomide—Vision blurred—Epirubicin—urinary bladder cancer	3.33e-05	0.000359	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—urinary bladder cancer	3.32e-05	0.000358	CcSEcCtD
Temozolomide—Cough—Methotrexate—urinary bladder cancer	3.3e-05	0.000355	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—urinary bladder cancer	3.29e-05	0.000355	CcSEcCtD
Temozolomide—Ill-defined disorder—Epirubicin—urinary bladder cancer	3.28e-05	0.000354	CcSEcCtD
Temozolomide—Convulsion—Methotrexate—urinary bladder cancer	3.27e-05	0.000353	CcSEcCtD
Temozolomide—Vomiting—Etoposide—urinary bladder cancer	3.27e-05	0.000353	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—urinary bladder cancer	3.27e-05	0.000353	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—urinary bladder cancer	3.27e-05	0.000353	CcSEcCtD
Temozolomide—Anaemia—Epirubicin—urinary bladder cancer	3.27e-05	0.000352	CcSEcCtD
Temozolomide—Agitation—Epirubicin—urinary bladder cancer	3.25e-05	0.00035	CcSEcCtD
Temozolomide—Rash—Etoposide—urinary bladder cancer	3.24e-05	0.00035	CcSEcCtD
Temozolomide—Dermatitis—Etoposide—urinary bladder cancer	3.24e-05	0.00035	CcSEcCtD
Temozolomide—Headache—Etoposide—urinary bladder cancer	3.22e-05	0.000348	CcSEcCtD
Temozolomide—Arthralgia—Methotrexate—urinary bladder cancer	3.22e-05	0.000347	CcSEcCtD
Temozolomide—Myalgia—Methotrexate—urinary bladder cancer	3.22e-05	0.000347	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—urinary bladder cancer	3.2e-05	0.000345	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	3.19e-05	0.000344	CcSEcCtD
Temozolomide—Malaise—Epirubicin—urinary bladder cancer	3.19e-05	0.000344	CcSEcCtD
Temozolomide—Discomfort—Methotrexate—urinary bladder cancer	3.18e-05	0.000343	CcSEcCtD
Temozolomide—Vertigo—Epirubicin—urinary bladder cancer	3.18e-05	0.000343	CcSEcCtD
Temozolomide—Leukopenia—Epirubicin—urinary bladder cancer	3.16e-05	0.000341	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—urinary bladder cancer	3.16e-05	0.000341	CcSEcCtD
Temozolomide—Palpitations—Epirubicin—urinary bladder cancer	3.12e-05	0.000337	CcSEcCtD
Temozolomide—Confusional state—Methotrexate—urinary bladder cancer	3.11e-05	0.000335	CcSEcCtD
Temozolomide—Cough—Epirubicin—urinary bladder cancer	3.08e-05	0.000333	CcSEcCtD
Temozolomide—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.08e-05	0.000332	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—urinary bladder cancer	3.08e-05	0.000332	CcSEcCtD
Temozolomide—Convulsion—Epirubicin—urinary bladder cancer	3.06e-05	0.00033	CcSEcCtD
Temozolomide—Infection—Methotrexate—urinary bladder cancer	3.06e-05	0.00033	CcSEcCtD
Temozolomide—Nausea—Etoposide—urinary bladder cancer	3.06e-05	0.00033	CcSEcCtD
Temozolomide—Hypertension—Epirubicin—urinary bladder cancer	3.05e-05	0.000329	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.03e-05	0.000327	CcSEcCtD
Temozolomide—Nervous system disorder—Methotrexate—urinary bladder cancer	3.02e-05	0.000326	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—urinary bladder cancer	3.02e-05	0.000326	CcSEcCtD
Temozolomide—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.02e-05	0.000326	CcSEcCtD
Temozolomide—Arthralgia—Epirubicin—urinary bladder cancer	3.01e-05	0.000325	CcSEcCtD
Temozolomide—Myalgia—Epirubicin—urinary bladder cancer	3.01e-05	0.000325	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—urinary bladder cancer	3.01e-05	0.000324	CcSEcCtD
Temozolomide—Anxiety—Epirubicin—urinary bladder cancer	3e-05	0.000323	CcSEcCtD
Temozolomide—Skin disorder—Methotrexate—urinary bladder cancer	2.99e-05	0.000323	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	2.99e-05	0.000322	CcSEcCtD
Temozolomide—Hyperhidrosis—Methotrexate—urinary bladder cancer	2.98e-05	0.000321	CcSEcCtD
Temozolomide—Discomfort—Epirubicin—urinary bladder cancer	2.97e-05	0.000321	CcSEcCtD
Temozolomide—Malaise—Doxorubicin—urinary bladder cancer	2.95e-05	0.000318	CcSEcCtD
Temozolomide—Dry mouth—Epirubicin—urinary bladder cancer	2.94e-05	0.000317	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—urinary bladder cancer	2.94e-05	0.000317	CcSEcCtD
Temozolomide—Anorexia—Methotrexate—urinary bladder cancer	2.94e-05	0.000317	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—urinary bladder cancer	2.93e-05	0.000316	CcSEcCtD
Temozolomide—Confusional state—Epirubicin—urinary bladder cancer	2.91e-05	0.000314	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—urinary bladder cancer	2.89e-05	0.000312	CcSEcCtD
Temozolomide—Anaphylactic shock—Epirubicin—urinary bladder cancer	2.88e-05	0.000311	CcSEcCtD
Temozolomide—Oedema—Epirubicin—urinary bladder cancer	2.88e-05	0.000311	CcSEcCtD
Temozolomide—Infection—Epirubicin—urinary bladder cancer	2.87e-05	0.000309	CcSEcCtD
Temozolomide—Cough—Doxorubicin—urinary bladder cancer	2.85e-05	0.000308	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—urinary bladder cancer	2.83e-05	0.000306	CcSEcCtD
Temozolomide—Nervous system disorder—Epirubicin—urinary bladder cancer	2.83e-05	0.000305	CcSEcCtD
Temozolomide—Thrombocytopenia—Epirubicin—urinary bladder cancer	2.82e-05	0.000305	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—urinary bladder cancer	2.82e-05	0.000305	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.81e-05	0.000303	CcSEcCtD
Temozolomide—Skin disorder—Epirubicin—urinary bladder cancer	2.8e-05	0.000302	CcSEcCtD
Temozolomide—Hyperhidrosis—Epirubicin—urinary bladder cancer	2.79e-05	0.000301	CcSEcCtD
Temozolomide—Insomnia—Methotrexate—urinary bladder cancer	2.79e-05	0.000301	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—urinary bladder cancer	2.78e-05	0.0003	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—urinary bladder cancer	2.78e-05	0.0003	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—urinary bladder cancer	2.77e-05	0.000299	CcSEcCtD
Temozolomide—Paraesthesia—Methotrexate—urinary bladder cancer	2.77e-05	0.000299	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	2.77e-05	0.000298	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—urinary bladder cancer	2.75e-05	0.000297	CcSEcCtD
Temozolomide—Anorexia—Epirubicin—urinary bladder cancer	2.75e-05	0.000297	CcSEcCtD
Temozolomide—Dyspnoea—Methotrexate—urinary bladder cancer	2.75e-05	0.000296	CcSEcCtD
Temozolomide—Somnolence—Methotrexate—urinary bladder cancer	2.74e-05	0.000296	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—urinary bladder cancer	2.72e-05	0.000294	CcSEcCtD
Temozolomide—Dyspepsia—Methotrexate—urinary bladder cancer	2.71e-05	0.000293	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—urinary bladder cancer	2.69e-05	0.00029	CcSEcCtD
Temozolomide—Decreased appetite—Methotrexate—urinary bladder cancer	2.68e-05	0.000289	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—urinary bladder cancer	2.67e-05	0.000288	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—urinary bladder cancer	2.67e-05	0.000288	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.66e-05	0.000287	CcSEcCtD
Temozolomide—Fatigue—Methotrexate—urinary bladder cancer	2.66e-05	0.000287	CcSEcCtD
Temozolomide—Infection—Doxorubicin—urinary bladder cancer	2.65e-05	0.000286	CcSEcCtD
Temozolomide—Pain—Methotrexate—urinary bladder cancer	2.64e-05	0.000284	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.63e-05	0.000283	CcSEcCtD
Temozolomide—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.62e-05	0.000282	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.61e-05	0.000282	CcSEcCtD
Temozolomide—Insomnia—Epirubicin—urinary bladder cancer	2.61e-05	0.000281	CcSEcCtD
Temozolomide—Skin disorder—Doxorubicin—urinary bladder cancer	2.59e-05	0.00028	CcSEcCtD
Temozolomide—Paraesthesia—Epirubicin—urinary bladder cancer	2.59e-05	0.000279	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—urinary bladder cancer	2.58e-05	0.000278	CcSEcCtD
Temozolomide—Dyspnoea—Epirubicin—urinary bladder cancer	2.57e-05	0.000277	CcSEcCtD
Temozolomide—Somnolence—Epirubicin—urinary bladder cancer	2.56e-05	0.000277	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—urinary bladder cancer	2.54e-05	0.000274	CcSEcCtD
Temozolomide—Feeling abnormal—Methotrexate—urinary bladder cancer	2.54e-05	0.000274	CcSEcCtD
Temozolomide—Dyspepsia—Epirubicin—urinary bladder cancer	2.54e-05	0.000274	CcSEcCtD
Temozolomide—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.52e-05	0.000272	CcSEcCtD
Temozolomide—Decreased appetite—Epirubicin—urinary bladder cancer	2.51e-05	0.00027	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.49e-05	0.000269	CcSEcCtD
Temozolomide—Fatigue—Epirubicin—urinary bladder cancer	2.49e-05	0.000268	CcSEcCtD
Temozolomide—Pain—Epirubicin—urinary bladder cancer	2.47e-05	0.000266	CcSEcCtD
Temozolomide—Constipation—Epirubicin—urinary bladder cancer	2.47e-05	0.000266	CcSEcCtD
Temozolomide—Urticaria—Methotrexate—urinary bladder cancer	2.45e-05	0.000264	CcSEcCtD
Temozolomide—Abdominal pain—Methotrexate—urinary bladder cancer	2.44e-05	0.000263	CcSEcCtD
Temozolomide—Body temperature increased—Methotrexate—urinary bladder cancer	2.44e-05	0.000263	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.43e-05	0.000262	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—urinary bladder cancer	2.41e-05	0.00026	CcSEcCtD
Temozolomide—Paraesthesia—Doxorubicin—urinary bladder cancer	2.4e-05	0.000259	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—urinary bladder cancer	2.38e-05	0.000257	CcSEcCtD
Temozolomide—Feeling abnormal—Epirubicin—urinary bladder cancer	2.38e-05	0.000256	CcSEcCtD
Temozolomide—Somnolence—Doxorubicin—urinary bladder cancer	2.37e-05	0.000256	CcSEcCtD
Temozolomide—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.36e-05	0.000254	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—urinary bladder cancer	2.35e-05	0.000253	CcSEcCtD
Temozolomide—Decreased appetite—Doxorubicin—urinary bladder cancer	2.32e-05	0.00025	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.3e-05	0.000249	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—urinary bladder cancer	2.3e-05	0.000248	CcSEcCtD
Temozolomide—Urticaria—Epirubicin—urinary bladder cancer	2.29e-05	0.000247	CcSEcCtD
Temozolomide—Pain—Doxorubicin—urinary bladder cancer	2.28e-05	0.000246	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—urinary bladder cancer	2.28e-05	0.000246	CcSEcCtD
Temozolomide—Abdominal pain—Epirubicin—urinary bladder cancer	2.28e-05	0.000246	CcSEcCtD
Temozolomide—Body temperature increased—Epirubicin—urinary bladder cancer	2.28e-05	0.000246	CcSEcCtD
Temozolomide—Hypersensitivity—Methotrexate—urinary bladder cancer	2.27e-05	0.000245	CcSEcCtD
Temozolomide—Asthenia—Methotrexate—urinary bladder cancer	2.21e-05	0.000239	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.2e-05	0.000237	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.18e-05	0.000235	CcSEcCtD
Temozolomide—Pruritus—Methotrexate—urinary bladder cancer	2.18e-05	0.000235	CcSEcCtD
Temozolomide—Hypersensitivity—Epirubicin—urinary bladder cancer	2.13e-05	0.000229	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—urinary bladder cancer	2.12e-05	0.000229	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—urinary bladder cancer	2.11e-05	0.000228	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—urinary bladder cancer	2.11e-05	0.000228	CcSEcCtD
Temozolomide—Diarrhoea—Methotrexate—urinary bladder cancer	2.11e-05	0.000227	CcSEcCtD
Temozolomide—Asthenia—Epirubicin—urinary bladder cancer	2.07e-05	0.000223	CcSEcCtD
Temozolomide—Pruritus—Epirubicin—urinary bladder cancer	2.04e-05	0.00022	CcSEcCtD
Temozolomide—Dizziness—Methotrexate—urinary bladder cancer	2.04e-05	0.00022	CcSEcCtD
Temozolomide—Diarrhoea—Epirubicin—urinary bladder cancer	1.97e-05	0.000213	CcSEcCtD
Temozolomide—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.97e-05	0.000212	CcSEcCtD
Temozolomide—Vomiting—Methotrexate—urinary bladder cancer	1.96e-05	0.000211	CcSEcCtD
Temozolomide—Rash—Methotrexate—urinary bladder cancer	1.94e-05	0.00021	CcSEcCtD
Temozolomide—Dermatitis—Methotrexate—urinary bladder cancer	1.94e-05	0.000209	CcSEcCtD
Temozolomide—Headache—Methotrexate—urinary bladder cancer	1.93e-05	0.000208	CcSEcCtD
Temozolomide—Asthenia—Doxorubicin—urinary bladder cancer	1.92e-05	0.000207	CcSEcCtD
Temozolomide—Dizziness—Epirubicin—urinary bladder cancer	1.91e-05	0.000206	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—urinary bladder cancer	1.89e-05	0.000204	CcSEcCtD
Temozolomide—Vomiting—Epirubicin—urinary bladder cancer	1.83e-05	0.000198	CcSEcCtD
Temozolomide—Nausea—Methotrexate—urinary bladder cancer	1.83e-05	0.000197	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—urinary bladder cancer	1.83e-05	0.000197	CcSEcCtD
Temozolomide—Rash—Epirubicin—urinary bladder cancer	1.82e-05	0.000196	CcSEcCtD
Temozolomide—Dermatitis—Epirubicin—urinary bladder cancer	1.82e-05	0.000196	CcSEcCtD
Temozolomide—Headache—Epirubicin—urinary bladder cancer	1.81e-05	0.000195	CcSEcCtD
Temozolomide—Dizziness—Doxorubicin—urinary bladder cancer	1.77e-05	0.00019	CcSEcCtD
Temozolomide—Nausea—Epirubicin—urinary bladder cancer	1.71e-05	0.000185	CcSEcCtD
Temozolomide—Vomiting—Doxorubicin—urinary bladder cancer	1.7e-05	0.000183	CcSEcCtD
Temozolomide—Rash—Doxorubicin—urinary bladder cancer	1.68e-05	0.000182	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—urinary bladder cancer	1.68e-05	0.000181	CcSEcCtD
Temozolomide—Headache—Doxorubicin—urinary bladder cancer	1.67e-05	0.00018	CcSEcCtD
Temozolomide—Nausea—Doxorubicin—urinary bladder cancer	1.59e-05	0.000171	CcSEcCtD
